antiviral and associated therapy - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.66 [0.34, 1.28]< 10%5 studies (5/-)89.2 %highnot evaluable lowcrucial-
deaths 0.75 [0.51, 1.11]< 10%20 studies (20/-)92.7 %highlow lowcrucial-
deaths (time to event analysis only) 0.64 [0.28, 1.48]< 10%3 studies (3/-)85.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.84 [0.59, 1.20]< 118%9 studies (9/-)83.1 %highnot evaluable lowimportant-
clinical improvement 1.23 [1.00, 1.53]> 150%12 studies (12/-)97.3 %highlow lowimportant-
clinical improvement (14-day) 1.19 [0.97, 1.46]> 128%7 studies (7/-)95.0 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.47 [1.06, 2.04]> 159%4 studies (4/-)99.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.19 [0.95, 1.49]> 165%9 studies (9/-)93.2 %highnot evaluable lowimportant-
clinical improvement (time to event analysis only) 1.25 [1.05, 1.48]> 148%8 studies (8/-)99.5 %highnot evaluable lowimportant-
hospital discharge 1.17 [0.86, 1.58]> 141%4 studies (4/-)83.6 %highnot evaluable lowimportant-
mechanical ventilation 0.77 [0.36, 1.68]< 139%8 studies (8/-)74.3 %highserious lowimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.17 [0.42, 3.26]> 116%3 studies (3/-)62.1 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.40 [0.02, 6.97]> 177%3 studies (3/-)26.9 %highnot evaluable lowimportant-
viral clearance 1.27 [0.96, 1.69]> 159%11 studies (11/-)95.0 %highcritical lowimportant-
viral clearance (time to event analysis only) 1.24 [0.87, 1.77]> 159%4 studies (4/-)88.5 %highnot evaluable lowimportant-
viral clearance by day 14 1.59 [0.84, 3.03]> 133%6 studies (6/-)92.1 %highserious lowimportant-
viral clearance by day 7 1.18 [0.87, 1.59]> 165%10 studies (10/-)85.9 %highlow lowimportant-
ICU admission 1.27 [0.80, 2.01]< 10%4 studies (4/-)15.9 %highnot evaluable lownon important-
recovery 1.15 [0.99, 1.33]> 10%2 studies (2/-)96.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.76 [0.47, 1.22]< 10%11 studies (11/-)87.1 %highcritical lowimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %some concernnot evaluable moderatenon important-
adverse events 1.99 [1.36, 2.91]< 172%15 studies (15/-)0.0 %highlow lownon important-
arrhythmia 2.24 [0.23, 21.69]< 10%1 study (1/-)24.5 %some concernnot evaluable moderatenon important-
elevated liver enzymes 3.48 [1.40, 8.64]< 10%1 study (1/-)0.4 %some concernnot evaluable moderatenon important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %some concernnot evaluable moderatenon important-
renal impairment 1.35 [0.47, 3.86]< 10%1 study (1/-)28.8 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 0.89 [0.31, 2.55]< 10%1 study (1/-)58.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.